RxDoctor Payments Data

Krithika Mullengada, MD

Internal Medicine · Succasunna, NJNPI 1992785562

Payments from drug & device makers

$926in general payments, 2019–2025

Across 55 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$236
  • Corcept Therapeutics$117
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$89
  • Novo Nordisk$58
  • Exact Sciences$55
  • Almatica Pharma LLC$42
  • plus $328 from 17 others

What the payments were for

  • Food & beverage$926100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$926 in reported general payments places this provider in the 65th percentile of 4,032 internal medicine providers in New Jersey.

See all internal medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$366,805
Medicare patients
719
Services billed
5,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban202$116,271
OzempicSemaglutide58$97,107
JardianceEmpagliflozin78$55,673
TradjentaLinagliptin66$55,561
MounjaroTirzepatide31$55,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$50,565
XareltoRivaroxaban59$42,147
TrulicityDulaglutide19$39,109
FarxigaDapagliflozin Propanediol28$31,160
Breo ElliptaFluticasone/Vilanterol43$24,844
JanuviaSitagliptin Phosphate32$22,969
MyrbetriqMirabegron30$14,597
JanumetSitagliptin Phos/Metformin Hcl15$12,747
Atorvastatin Calcium829$9,653
Duloxetine Hcl250$8,355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$58$97,10758 claims
Lilly USA, LLCMounjaro, Trulicity$29$94,15050 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Shingrix$236$88,078127 claims
Johnson & JohnsonXarelto$16$42,14759 claims
AstraZenecaFarxiga$15$31,16028 claims
AbbVieLinzess, Alphagan P$37$11,62428 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,032 internal medicine providers in New Jersey.

Other internal medicine in Succasunna

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →